{ "items": [ "\n\n
\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n11 February 2021
\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.
\n \n\n \n \n10 February 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n10 February 2021
\n \n \n \nThe results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n10 February 2021
\n \n \n \nA clinical trial has commenced this week to test whether a drug called Almitrine can help people who are seriously ill with COVID-19 to recover from the disease.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n9 February 2021
\n \n \n \nThe results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.
\n \n\n \n \n9 February 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n9 February 2021
\n \n \n \nEarly treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n9 February 2021
\n \n \n \nA team of medical research and statistical modelling experts at Oxford University and the Alan Turing Institute have conducted a joint analysis to assess the impact of the NHS COVID-19 contact tracing app.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Staff and student stories\n \n \n\n \n\n\n
\n \n\n \n9 February 2021
\n \n \n \nVignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.
\n \n\n \n \n9 February 2021
\n \n \n \n\n \n \n9 February 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n8 February 2021
\n \n \n \nIn an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n5 February 2021
\n \n \n \nResearchers have developed a machine learning algorithm that could improve clinicians\u2019 ability to identify hospitalised patients who need intensive care.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n5 February 2021
\n \n \n \nA preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nNew research from the Kennedy Institute of Rheumatology (Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences) identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of ageing and highlights organ-specific vascular changes with age.
\n \n\n \n \n4 February 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nIn a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nEnara Bio, a start-up located in the University\u2019s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over \u20ac876M (\u00a3787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nThe University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Public Engagement with Research\n \n \n\n \n\n\n
\n \n\n \n3 February 2021
\n \n \n \nSeven projects from the Medical Sciences Division have received funding in the 2020-21 round of the Public Engagement with Research Seed Fund for innovative projects to engage the public with medical research.
\n \n\n \n \n